Shopping Cart 0
Cart Subtotal
USD 0

Pseudomonas aeruginosa Infections - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 7, 71, 22 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 15, 15 and 1 molecules, respectively.

Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Pseudomonas aeruginosa Infections-Overview 7

Pseudomonas aeruginosa Infections-Therapeutics Development 8

Pseudomonas aeruginosa Infections-Therapeutics Assessment 25

Pseudomonas aeruginosa Infections-Companies Involved in Therapeutics Development 33

Pseudomonas aeruginosa Infections-Drug Profiles 57

Pseudomonas aeruginosa Infections-Dormant Projects 244

Pseudomonas aeruginosa Infections-Discontinued Products 249

Pseudomonas aeruginosa Infections-Product Development Milestones 250

Appendix 262


List Of Figure

List of Figures

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Achaogen Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Acies Bio doo, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AiCuris GmbH & Co KG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AlgiPharma AS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AmpliPhi Biosciences Corp, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Appili Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AstraZeneca Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Atterx Biotherapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Biolytics Pharma, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by BlueWillow Biologics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by C3J Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by ContraFect Corp, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Destiny Pharma Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Evaxion Biotech ApS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Evotec AG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Helix BioMedix Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Hsiri Therapeutics LLC, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Immun System IMS AB, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Inhibrx LP, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Insmed Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by KBP BioSciences Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Lakewood-Amedex Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by LegoChem Biosciences Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Melinta Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Microbiotix Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Nosopharm SAS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Novabiotics Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Novartis AG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Peptilogics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Pfizer Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Pherecydes Pharma SA, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Phico Therapeutics Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Redx Pharma Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Sealife PHARMA GMBH, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Sequoia Sciences Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Shionogi & Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Soligenix Inc, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pseudomonas aeruginosa Infections Therapeutic Products under Development, Key Players in Pseudomonas aeruginosa Infections Therapeutics, Pseudomonas aeruginosa Infections Pipeline Overview, Pseudomonas aeruginosa Infections Pipeline, Pseudomonas aeruginosa Infections Pipeline Assessment


Companies

Achaogen Inc

Acies Bio doo

Aeolus Pharmaceuticals Inc

AiCuris GmbH & Co KG

AlgiPharma AS

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Atterx Biotherapeutics Inc

Biolytics Pharma

BlueWillow Biologics Inc

C3J Therapeutics Inc

Catabasis Pharmaceuticals Inc

ContraFect Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Destiny Pharma Plc

Evaxion Biotech ApS

Evotec AG

F. Hoffmann-La Roche Ltd

Helix BioMedix Inc

Hsiri Therapeutics LLC

Immun System IMS AB

Inhibrx LP

Insmed Inc

KBP BioSciences Co Ltd

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novabiotics Ltd

Novartis AG

Peptilogics Inc

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Redx Pharma Plc

Sealife PHARMA GMBH

Sequoia Sciences Inc

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Syntiron LLC

TAXIS Pharmaceuticals Inc

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Visterra Inc

Wockhardt Ltd

Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 7, 71, 22 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 15, 15 and 1 molecules, respectively.

Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 6

Pseudomonas aeruginosa Infections-Overview 7

Pseudomonas aeruginosa Infections-Therapeutics Development 8

Pseudomonas aeruginosa Infections-Therapeutics Assessment 25

Pseudomonas aeruginosa Infections-Companies Involved in Therapeutics Development 33

Pseudomonas aeruginosa Infections-Drug Profiles 57

Pseudomonas aeruginosa Infections-Dormant Projects 244

Pseudomonas aeruginosa Infections-Discontinued Products 249

Pseudomonas aeruginosa Infections-Product Development Milestones 250

Appendix 262


List Of Figure

List of Figures

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Achaogen Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Acies Bio doo, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AiCuris GmbH & Co KG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AlgiPharma AS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AmpliPhi Biosciences Corp, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Appili Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by AstraZeneca Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Atterx Biotherapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Biolytics Pharma, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by BlueWillow Biologics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by C3J Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by ContraFect Corp, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Destiny Pharma Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Evaxion Biotech ApS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Evotec AG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Helix BioMedix Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Hsiri Therapeutics LLC, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Immun System IMS AB, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Inhibrx LP, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Insmed Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by KBP BioSciences Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Lakewood-Amedex Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by LegoChem Biosciences Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Melinta Therapeutics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Microbiotix Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Nosopharm SAS, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Novabiotics Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Novartis AG, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Peptilogics Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Pfizer Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Pherecydes Pharma SA, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Phico Therapeutics Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Redx Pharma Plc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Sealife PHARMA GMBH, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Sequoia Sciences Inc, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Shionogi & Co Ltd, H2 2018

Pseudomonas aeruginosa Infections-Pipeline by Soligenix Inc, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Pseudomonas aeruginosa Infections Therapeutic Products under Development, Key Players in Pseudomonas aeruginosa Infections Therapeutics, Pseudomonas aeruginosa Infections Pipeline Overview, Pseudomonas aeruginosa Infections Pipeline, Pseudomonas aeruginosa Infections Pipeline Assessment


Companies

Achaogen Inc

Acies Bio doo

Aeolus Pharmaceuticals Inc

AiCuris GmbH & Co KG

AlgiPharma AS

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Atterx Biotherapeutics Inc

Biolytics Pharma

BlueWillow Biologics Inc

C3J Therapeutics Inc

Catabasis Pharmaceuticals Inc

ContraFect Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Destiny Pharma Plc

Evaxion Biotech ApS

Evotec AG

F. Hoffmann-La Roche Ltd

Helix BioMedix Inc

Hsiri Therapeutics LLC

Immun System IMS AB

Inhibrx LP

Insmed Inc

KBP BioSciences Co Ltd

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novabiotics Ltd

Novartis AG

Peptilogics Inc

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Redx Pharma Plc

Sealife PHARMA GMBH

Sequoia Sciences Inc

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Syntiron LLC

TAXIS Pharmaceuticals Inc

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Visterra Inc

Wockhardt Ltd